{"id":11730,"date":"2026-11-12T06:30:49","date_gmt":"2026-11-12T06:30:49","guid":{"rendered":"https:\/\/www.marrow.com\/blog\/?p=11730"},"modified":"2026-11-16T05:36:11","modified_gmt":"2026-11-16T05:36:11","slug":"recent-updates-november-26","status":"publish","type":"post","link":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/","title":{"rendered":"Recent Updates | November 2026"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"480\" src=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png\" alt=\"Recent Updates_November_2026\" class=\"wp-image-11734\" srcset=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png 1280w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-300x113.png 300w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-700x263.png 700w, https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-768x288.png 768w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Here are a few NEET-PG-related, clinically important updates from recent months.&nbsp;<br><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Contents:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"#Rusfertide\" data-type=\"internal\" data-id=\"#Rusfertide\">Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera<\/a><\/li>\n\n\n\n<li><a href=\"#atrialfibrillation\" data-type=\"internal\" data-id=\"#atrialfibrillation\">AHA\/ACC recommendations for patients with atrial fibrillation (2026)<\/a><\/li>\n\n\n\n<li><a href=\"#Infectiveendocarditis\" data-type=\"internal\" data-id=\"#Infectiveendocarditis\">AHA 2026 Guidelines for Infective Endocarditis<\/a><\/li>\n\n\n\n<li><a href=\"#malaria\" data-type=\"internal\" data-id=\"#malaria\">WHO 2026 guidelines on Malaria<\/a><\/li>\n\n\n\n<li><a href=\"#cardiogenicshock\" data-type=\"internal\" data-id=\"#cardiogenicshock\">ESC criteria for the diagnosis of Cardiogenic Shock (2026)<\/a><\/li>\n\n\n\n<li><a href=\"#Reteovarii\">Rete ovarii: Reconsidering its role in ovarian function<\/a><\/li>\n\n\n\n<li><a href=\"#Rome5\" data-type=\"internal\" data-id=\"#Rome5\">Rome V criteria for DGBIs<\/a><\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-9808a7695c3cd1618a2356465564c5f2\" id=\"Rusfertide\" style=\"color:#0c1c47\"><strong>Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA has approved rusfertide, a first-in-class hepcidin mimetic, for erythrocytosis in adults with polycythemia vera (PV).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MOA<strong>:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Blocks ferroportin (iron transporter).<\/li>\n\n\n\n<li>Reduces iron availability for RBC production.<\/li>\n\n\n\n<li>Lowers hematocrit levels, reducing blood viscosity.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Dose<strong>:<\/strong> Starting dose: 19 mg weekly SC; maximum: 108 mg weekly.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Adverse<strong> <\/strong>effects: Thrombocytosis, anaemia and injection-site reactions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Contraindications<strong>:<\/strong> Pregnancy (embryo-fetal toxicity), breastfeeding and paediatric age groups.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-d3ec0a069c4fcbdb5b32b8aad79e6f5e\" id=\"atrialfibrillation\" style=\"color:#0c1c47\"><strong>AHA\/ACC recommendations for patients with atrial fibrillation (2026)<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">AHA\/ACC have updated clinical performance and quality measures for atrial fibrillation (AF).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Stroke prophylaxis:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Risk assessment: CHA\u2082DS\u2082-VASc, ATRIA or GARFIELD-AF.<\/li>\n\n\n\n<li>Initiate anticoagulation if annual stroke risk is &gt;2%.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Safer use of blood thinners:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>AF Post-PCI: Discontinue aspirin within 1- 4 weeks; prefer DOAC + P2Y12 inhibitor over triple therapy.<\/li>\n\n\n\n<li>AF with chronic coronary disease: Prefer anticoagulation monotherapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Other recommendations:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Newly diagnosed AF: Transthoracic echocardiogram, CBC and TSH.<\/li>\n\n\n\n<li>Lifestyle changes: \u226510% weight loss, 210 minutes\/week of moderate-to-vigorous exercise, quit smoking and regular alcohol intake.<\/li>\n\n\n\n<li>Dofetilide initiation\/dose escalation: Only during a 3-day hospital stay.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-2343ca15ca5a72a95452f48c8697575b\" id=\"Infectiveendocarditis\" style=\"color:#0c1c47\"><strong>AHA 2026 Guidelines for Infective Endocarditis<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">AHA has updated its guidelines for diagnosis and management of infective endocarditis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Diagnosis<strong>:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adopts 2023 Duke\/ISCVID criteria, replacing 2000 modified Duke criteria.<\/li>\n\n\n\n<li>Enterococcus faecalis is now considered a typical IE pathogen, regardless of whether it is community-acquired or associated with a known primary focus.<\/li>\n\n\n\n<li>Blood collection for culture is simplified by removing the strict timing and separate-venipuncture-site rules.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Antibiotic regimen updates:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Staphylococcal PVE: Gentamicin not recommended.<\/li>\n\n\n\n<li>Staphylococcal NVE: Postoperative monotherapy preferred.<\/li>\n\n\n\n<li>Streptococci\/ S. gallolyticus: Ceftriaxone monotherapy for penicillin-intermediate strains if 3rd-generation cephalosporin MIC \u22640.5 mg\/L.<\/li>\n\n\n\n<li>Left-sided IE: Partial oral therapy after \u226510 days of IV therapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Other updates: Complete CIED extraction preferred; colonoscopy for all patients with <em>E. faecalis<\/em>\/<em>S. gallolyticus<\/em> IE and percutaneous mechanical aspiration when surgery is risky.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-9630e6552b33b02d3edf9ef45d120963\" id=\"malaria\" style=\"color:#0c1c47\"><strong>WHO 2026 guidelines on Malaria<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">WHO has updated four major recommendations for malaria prevention and management.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key updates:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>HIV-positive pregnant women: Dihydroartemisinin-piperaquine may be used if local malaria resistance is high and is compatible with HIV medication. Sulfadoxine-pyrimethamine is contraindicated with co-trimoxazole.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Low-transmission areas: Primaquine 0.25 mg\/kg single dose with ACT for <em>P. falciparum<\/em>. G6PD testing is not mandatory. Excludes pregnancy, infants &lt;1 month and breastfeeding women with infants &lt;1 month.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Infants &lt;5 kg: In uncomplicated P. falciparum malaria, ACT at the same mg\/kg target dose as infants &gt;5 kg. Prefer artemether-lumefantrine (1:12 ratio) designed specifically for infants &lt;5 kg, if available.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Vaccination: First dose can be given before 5 months. Three doses benefit children in vulnerable settings if the fourth dose cannot be delivered.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-6332067e9777295aa6595501ead467e3\" id=\"cardiogenicshock\" style=\"color:#0c1c47\"><strong>ESC criteria for the diagnosis of Cardiogenic Shock (2026)<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">ESC has introduced standardised diagnostic criteria for cardiogenic shock. All three parameters must be fulfilled, along with suggestive clinical and point-of-care assessments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">1. Cardiac dysfunction:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Severe LV\/RV\/biventricular dysfunction, severe valvular disease or mechanical complications.<\/li>\n\n\n\n<li>Recurrent\/persistent ventricular arrhythmias.<\/li>\n\n\n\n<li>Exclude obstructive shock.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">2. Haemodynamic abnormality: \u22652 of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>SBP &lt;90 and\/ or MAP &lt;65 mmHg for &gt;30 min.<\/li>\n\n\n\n<li>SBP \u226590 and\/ or MAP \u226565 mmHg on vasoactive drugs.<\/li>\n\n\n\n<li>Raised filling pressures.<\/li>\n\n\n\n<li>Cardiac index &lt;2.2 L\/min\/m\u00b2 without vasoactive drugs.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">3. Hypoperfusion: \u22651 clinical sign AND \u22651 metabolic parameter.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-c0e3e7a40a4ac893873593cbf869c88d\" id=\"Reteovarii\" style=\"color:#0c1c47\"><strong>Rete ovarii: Reconsidering its role in ovarian function<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The rete ovarii (RO), previously considered a functionless vestigial structure, is being reconsidered as a potentially functional organ and the female homologue of the rete testis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Development: Arises from mesonephric tubules and persists into adulthood.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anatomy: A network of epithelial cells and tubules attached to the ovarian hilum, comprising:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Extraovarian rete: Columnar epithelial cells.<\/li>\n\n\n\n<li>Connecting rete: Pseudocolumnar cells.<\/li>\n\n\n\n<li>Intraovarian rete: Squamous epithelial cells forming branching networks of thin cell cords.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Function: Secretory material within its tubules and experimental findings suggest that RO sends material to the ovary and may contribute to ovarian function.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center has-text-color has-link-color wp-elements-548696ee655488e5df0eedcc9f71ce90\" id=\"Rome5\" style=\"color:#0c1c47\"><strong>Rome V criteria for DGBIs<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">The Rome Foundation has released Rome V criteria, 10 years after Rome IV (2016). Key changes include updated terminology, revised IBS diagnostic criteria and a shift towards positive diagnostic approach rather than diagnosis of exclusion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Terminology updates:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Functional GI disorders \u2192 Disorders of gut-brain interaction (DGBIs).<\/li>\n\n\n\n<li>Functional constipation \u2192 Chronic constipation.<\/li>\n\n\n\n<li>Functional nausea \u2192 Chronic nausea syndrome.<\/li>\n\n\n\n<li>Unspecified bowel disorder \u2192 Unclassified bowel disorder.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Updated IBS criteria: Recurrent abdominal pain\/discomfort \u22653 days\/month in the last 3 months, with \u22652 features:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Relation to defecation<\/li>\n\n\n\n<li>Associated with a change in stool frequency<\/li>\n\n\n\n<li>Associated with a change in stool form (appearance)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical diagnosis is possible after 8 weeks if symptoms are bothersome.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">New disorders: Inability to belch syndrome, abdominal migraine and anorectal sensory dysfunction disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Management: Mild: education &amp; referral to a dietitian; moderate: behavioural therapy and pharmacotherapy; severe: central neuromodulators and specialist referral.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To see the complete list of updates, check out the Recent Updates section on your Marrow app.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here are a few NEET-PG-related, clinically important updates from recent months.&nbsp; Contents: Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera The&#46;&#46;&#46;<\/p>\n","protected":false},"author":27,"featured_media":11734,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","_exactmetrics_skip_tracking":false,"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[574],"tags":[],"class_list":["post-11730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-neet-pg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Recent Updates | November 2026 -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recent Updates | November 2026 -\" \/>\n<meta property=\"og:description\" content=\"Here are a few NEET-PG-related, clinically important updates from recent months.&nbsp; Contents: Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera The&#046;&#046;&#046;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/marrowmed\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T06:30:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-16T05:36:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Team Marrow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Team Marrow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/\"},\"author\":{\"name\":\"Team Marrow\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/person\\\/cd6a97d1afd5417c0e14c18b3c4f4f0a\"},\"headline\":\"Recent Updates | November 2026\",\"datePublished\":\"2026-11-12T06:30:49+00:00\",\"dateModified\":\"2026-11-16T05:36:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/\"},\"wordCount\":821,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/RU-Nov-26.png\",\"articleSection\":[\"NEET PG\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/\",\"name\":\"Recent Updates | November 2026 -\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/RU-Nov-26.png\",\"datePublished\":\"2026-11-12T06:30:49+00:00\",\"dateModified\":\"2026-11-16T05:36:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/RU-Nov-26.png\",\"contentUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/RU-Nov-26.png\",\"width\":1280,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/recent-updates-november-26\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recent Updates | November 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/\",\"name\":\"Marrow\",\"description\":\"The Gold Standard for new pattern NEET PG - NEXT\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#organization\",\"name\":\"Marrow\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/image-2.png\",\"contentUrl\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/wp-content\\\/uploads\\\/2018\\\/02\\\/image-2.png\",\"width\":1024,\"height\":1024,\"caption\":\"Marrow\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/marrowmed\\\/\",\"https:\\\/\\\/www.instagram.com\\\/marrowmed\\\/?hl=en\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCkdqtg0tEcRb1wMCFr2wN2A\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/#\\\/schema\\\/person\\\/cd6a97d1afd5417c0e14c18b3c4f4f0a\",\"name\":\"Team Marrow\",\"url\":\"https:\\\/\\\/www.marrow.com\\\/blog\\\/author\\\/kishan-shob\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recent Updates | November 2026 -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/","og_locale":"en_US","og_type":"article","og_title":"Recent Updates | November 2026 -","og_description":"Here are a few NEET-PG-related, clinically important updates from recent months.&nbsp; Contents: Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera The&#46;&#46;&#46;","og_url":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/","article_publisher":"https:\/\/www.facebook.com\/marrowmed\/","article_published_time":"2026-11-12T06:30:49+00:00","article_modified_time":"2026-11-16T05:36:11+00:00","og_image":[{"width":1280,"height":480,"url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png","type":"image\/png"}],"author":"Team Marrow","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Team Marrow","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#article","isPartOf":{"@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/"},"author":{"name":"Team Marrow","@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/person\/cd6a97d1afd5417c0e14c18b3c4f4f0a"},"headline":"Recent Updates | November 2026","datePublished":"2026-11-12T06:30:49+00:00","dateModified":"2026-11-16T05:36:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/"},"wordCount":821,"commentCount":0,"publisher":{"@id":"https:\/\/www.marrow.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#primaryimage"},"thumbnailUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png","articleSection":["NEET PG"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/","url":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/","name":"Recent Updates | November 2026 -","isPartOf":{"@id":"https:\/\/www.marrow.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#primaryimage"},"image":{"@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#primaryimage"},"thumbnailUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png","datePublished":"2026-11-12T06:30:49+00:00","dateModified":"2026-11-16T05:36:11+00:00","breadcrumb":{"@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#primaryimage","url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png","contentUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png","width":1280,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/www.marrow.com\/blog\/recent-updates-november-26\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marrow.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Recent Updates | November 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marrow.com\/blog\/#website","url":"https:\/\/www.marrow.com\/blog\/","name":"Marrow","description":"The Gold Standard for new pattern NEET PG - NEXT","publisher":{"@id":"https:\/\/www.marrow.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marrow.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.marrow.com\/blog\/#organization","name":"Marrow","url":"https:\/\/www.marrow.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2018\/02\/image-2.png","contentUrl":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2018\/02\/image-2.png","width":1024,"height":1024,"caption":"Marrow"},"image":{"@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/marrowmed\/","https:\/\/www.instagram.com\/marrowmed\/?hl=en","https:\/\/www.youtube.com\/channel\/UCkdqtg0tEcRb1wMCFr2wN2A"]},{"@type":"Person","@id":"https:\/\/www.marrow.com\/blog\/#\/schema\/person\/cd6a97d1afd5417c0e14c18b3c4f4f0a","name":"Team Marrow","url":"https:\/\/www.marrow.com\/blog\/author\/kishan-shob\/"}]}},"jetpack_publicize_connections":[],"uagb_featured_image_src":{"full":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png",1280,480,false],"thumbnail":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-150x150.png",150,150,true],"medium":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-300x113.png",300,113,true],"medium_large":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-768x288.png",768,288,true],"large":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-700x263.png",700,263,true],"1536x1536":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png",1280,480,false],"2048x2048":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png",1280,480,false],"thumb-small":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-80x80.png",80,80,true],"thumb-standard":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-320x320.png",320,320,true],"thumb-medium":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-520x245.png",520,245,true],"thumb-large":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-720x340.png",720,340,true],"thumb-xlarge":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26-980x450.png",980,450,true],"thumb-xxlarge":["https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png",1280,480,false]},"uagb_author_info":{"display_name":"Team Marrow","author_link":"https:\/\/www.marrow.com\/blog\/author\/kishan-shob\/"},"uagb_comment_info":2,"uagb_excerpt":"Here are a few NEET-PG-related, clinically important updates from recent months.&nbsp; Contents: Rusfertide: 1st-in-class FDA-approved drug for polycythemia vera The&#46;&#46;&#46;","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pawmxr-33c","jetpack_featured_media_url":"https:\/\/www.marrow.com\/blog\/wp-content\/uploads\/2026\/11\/RU-Nov-26.png","_links":{"self":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts\/11730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/comments?post=11730"}],"version-history":[{"count":9,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts\/11730\/revisions"}],"predecessor-version":[{"id":11746,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/posts\/11730\/revisions\/11746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/media\/11734"}],"wp:attachment":[{"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/media?parent=11730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/categories?post=11730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marrow.com\/blog\/wp-json\/wp\/v2\/tags?post=11730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}